Posted: 27 Mar 2018 08:25 PM PDT
FDA to use the “least burdensome” approach in reviewing device applications. This legislation resulted in little change in behavior. In 2012, Congress enacted new legislation with the same outcome.In 1997, Congress directed
In 21st Century Cures, Congress addressed the “least burdensome” approach for the third time. On December 15, 2017, FDA issued a Draft Guidance Document (see our previous post here).
The draft guidance contains some potentially positive implements, provided that they are actually implemented. Yet, based on FDA’s past conduct, doubts are inevitable. Hyman, Phelps & McNamara, P.C. has submitted comments to FDA regarding the draft guidance document.
Whether the “least burdensome” approach will truly be incorporated into practice or remain a largely meaningless phrase will not be known for some time. If truly embraced by FDA, the “least burdensome” approach could have a significant, positive impact on device regulation. The content of the final guidance, though, will provide important clues.
Specific PHGKB|Rare Diseases PHGKB|PHGKB
Hace 4 horas